Q-omics provides the consensus-scored GOLT1B profile across patient tissues and cancer cell-line models. GOLT1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GOLT1B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GOLT1B RNA expression shows 19,374 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where GOLT1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLT1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLT1B survival associations across molecular data types. GOLT1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLT1B RNA expression–survival associations across cancer types. High GOLT1B expression shows unfavorable associations in MESO, KIRP, UVM, CESC, HNSC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GOLT1B RNA expression.
This table summarizes GOLT1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GOLT1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLT1B shows higher tumor expression in HNSC, BLCA, KIRP, KIRC, LIHC and LUAD. The HNSC box plot shows higher GOLT1B RNA expression in tumor versus normal tissue (log2 FC = +1.673, t-test p < 0.001).
This table shows molecular features associated with GOLT1B in patient tissues and cancer cell lines. In patient samples, GOLT1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLT1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
